Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells

Journal of Psychiatric Research

Volumn 47, Issue 4, 2013, Pages 425-437

  Gardiner, Erin J ^a,b,c   Cairns, Murray J ^a,b,c   Liu, Bing ^a,b,c   Beveridge, Natalie J ^a,b,c   Carr, Vaughan ^a,e   Kelly, Brian ^b,c   Scott, Rodney J ^a,b,c,d   Tooney, Paul A ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Expression; Immune; Inflammation; MRNA; PBMCs; Schizophrenia

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; ALPHA DEFENSIN; ARGONAUTE 2 PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; AZUROCIDIN; CATHEPSIN D; CORTICOSTATIN; CYSTATIN B; DEFENSIN; DEFENSIN ALPHA 4; DYNEIN ADENOSINE TRIPHOSPHATASE; GUANOSINE PHOSPHATE REDUCTASE; HAPTOCORRIN; INTERLEUKIN 16; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEROXIREDOXIN 5; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROPERDIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RIBONUCLEASE A; S100A12 PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SYNAPTOBREVIN; TRANSCRIPTION FACTOR IIH; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VESICLE ASSOCIATED MEMBRANE PROTEIN 5;

ADULT; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UPREGULATION;

EID: 84874424599     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.11.007     Document Type: Article

References (120)

1. Aldred P.M., Hollox E.J., Armour J.A. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Human Molecular Genetics 2005, 14:2045-2052.
2. Arion D., Unger T., Lewis D.A., Levitt P., Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biological Psychiatry 2007, 62:711-721.
3. Aude-Garcia C., Collin-Faure V., Bausinger H., Hanau D., Rabilloud T., Lemercier C. Dual roles for MEF2A and MEF2D during human macrophage terminal differentiation and c-Jun expression. The Biochemical Journal 2010, 430:237-244.
4. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biological Psychiatry 2008, 64:820-822.
5. Beveridge N.J., Gardiner E., Carroll A.P., Tooney P.A., Cairns M.J. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Molecular Psychiatry 2010, 15:1176-1189.
6. Beveridge N.J., Tooney P.A., Carroll A.P., Tran N., Cairns M.J. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cellular Signalling 2009, 21:1837-1845.
7. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Frontiers in Behavioral Neuroscience 2009, 3:14.
8. Bousman C.A., Chana G., Glatt S.J., Chandler S.D., Lucero G.R., Tatro E., et al. Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2010, 153B:494-502.
9. Bowden N.A., Scott R.J., Tooney P.A. Altered gene expression in the superior temporal gyrus in schizophrenia. BMC Genomics 2008, 9:199.
10. Bowden N.A., Weidenhofer J., Scott R.J., Schall U., Todd J., Michie P.T., et al. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophrenia Research 2006, 82:175-183.
11. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. American Journal of Psychiatry 2010, 167:261-280.
12. Byrne M., Agerbo E., Bennedsen B., Eaton W.W., Mortensen P.B. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophrenia Research 2007, 97:51-59.
13. Cenik E.S., Zamore P.D. Argonaute proteins. Current Biology: CB 2011, 21:R446-R449.
14. Chen M.L., Tsai T.C., Wang L.K., Lin Y.Y., Tsai Y.M., Lee M.C., et al. Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-gamma production in peripheral blood mononuclear cells. Immunopharmacology and Immunotoxicology 2012, 34:686-694.
15. Choi J., Lee H.W., Suk K. Increased plasma levels of lipocalin 2 in mild cognitive impairment. Journal of the Neurological Sciences 2011, 305:28-33.
16. Consortium I.S. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008, 455:237-241.
17. Cowland J.B., Sorensen O.E., Sehested M., Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. Journal of Immunology 2003, 171:6630-6639.
18. Craddock R.M., Huang J.T., Jackson E., Harris N., Torrey E.F., Herberth M., et al. Increased alpha-defensins as a blood marker for schizophrenia susceptibility. Molecular & Cellular Proteomics: MCP 2008, 7:1204-1213.
19. Cruikshank W., Little F. Interleukin-16: the ins and outs of regulating T-cell activation. Critical Reviews in Immunology 2008, 28:467-483.
20. Deretic V. Autophagy in innate and adaptive immunity. Trends in Immunology 2005, 26:523-528.
21. Diederichs S., Haber D.A. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 2007, 131:1097-1108.
22. Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Ait-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. Journal of Experimental Medicine 1998, 188:373-386.
23. Doorduin J., de Vries E.F., Willemsen A.T., de Groot J.C., Dierckx R.A., Klein H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 2009, 50:1801-1807.
24. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Review of Neurotherapeutics 2010, 10:59-76.
25. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behavior, and Immunity 2006, 20:532-545.
26. Du P., Kibbe W.A., Lin S.M. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24:1547-1548.
27. Fallin M.D., Lasseter V.K., Liu Y., Avramopoulos D., McGrath J., Wolyniec P.S., et al. Linkage and association on 8p21.2-p21.1 in schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2011, 156:188-197.
28. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Molecular Psychiatry 2012, [Epub ahead of print]. 10.1038/mp.2012.110.
29. Fiore R., Khudayberdiev S., Christensen M., Siegel G., Flavell S.W., Kim T.K., et al. Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. EMBO Journal 2009, 28:697-710.
30. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
31. Frank F., Sonenberg N., Nagar B. Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature 2010, 465:818-822.
32. Gardiner E., Beveridge N.J., Wu J.Q., Carr V., Scott R.J., Tooney P.A., et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Molecular Psychiatry 2011, 18:827-840.
33. Gladkevich A., Kauffman H.F., Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Progress in Neuropsychopharmacology & Biological Psychiatry 2004, 28:559-576.
34. Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15533-15538.
35. Grady W.M., Parkin R.K., Mitchell P.S., Lee J.H., Kim Y.H., Tsuchiya K.D., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008, 27:3880-3888.
36. Guyon A., Massa F., Rovere C., Nahon J.L. How cytokines can influence the brain: a role for chemokines?. Journal of Neuroimmunology 2008, 198:46-55.
37. Han W., Lou Y., Tang J., Zhang Y., Chen Y., Li Y., et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. The Biochemical Journal 2001, 357:127-135.
38. Heidenreich K.A., Linseman D.A. Myocyte enhancer factor-2 transcription factors in neuronal differentiation and survival. Molecular Neurobiology 2004, 29:155-166.
39. Horesh Y., Katsel P., Haroutunian V., Domany E. Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2011, 18:410-424.
40. Hou R., Baldwin D.S. A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology 2012, 27:6-14.
41. Jia P., Wang L., Meltzer H.Y., Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophrenia Research 2010, 122:38-42.
42. Kaser A., Dunzendorfer S., Offner F.A., Ryan T., Schwabegger A., Cruikshank W.W., et al. A role for IL-16 in the cross-talk between dendritic cells and T cells. Journal of Immunology 1999, 163:3232-3238.
43. Ke X., Jia L., Jing H., Liu Y., Zhang Y., Di C. Effects of novel human chemokine-like factor 1 (CKLF1) on bone marrow hematopoietic stem cell/progenitor cell in vitro. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi 2002, 23:301-303.
44. Kinney D.K., Hintz K., Shearer E.M., Barch D.H., Riffin C., Whitley K., et al. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Medical Hypotheses 2010, 74:555-563.
45. Klotman M.E., Chang T.L. Defensins in innate antiviral immunity. Nature Reviews. Immunology 2006, 6:447-456.
46. Krause M., Dent E.W., Bear J.E., Loureiro J.J., Gertler F.B. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annual Review of Cell and Developmental Biology 2003, 19:541-564.
47. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. American Journal of Psychiatry 2000, 157:683-694.
48. Kurian S.M., Heilman R., Mondala T.S., Nakorchevsky A., Hewel J.A., Campbell D., et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009, 4:e6212.
49. Kurian S.M., Le-Niculescu H., Patel S.D., Bertram D., Davis J., Dike C., et al. Identification of blood biomarkers for psychosis using convergent functional genomics. Molecular Psychiatry 2011, 16:37-58.
50. Lam B.Y., Chawla S. MEF2D expression increases during neuronal differentiation of neural progenitor cells and correlates with neurite length. Neuroscience Letters 2007, 427:153-158.
51. Laumbacher B., Muller N., Bondy B., Schlesinger B., Gu S., Fellerhoff B., et al. Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients. Journal of Medical Genetics 2003, 40:217-219.
52. Lencz T., Morgan T.V., Athanasiou M., Dain B., Reed C.R., Kane J.M., et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Molecular Psychiatry 2007, 12:572-580.
53. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F.M., Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Molecular Psychiatry 2009, 15:1088-1100.
54. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
55. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. American Journal of Human Genetics 2003, 73:34-48.
56. Li T., Li Z., Chen P., Zhao Q., Wang T., Huang K., et al. Common variants in major histocompatibility complex region and TCF4 gene are significantly associated with schizophrenia in Han Chinese. Biological Psychiatry 2010, 68:671-673.
57. Liew C.C., Ma J., Tang H.C., Zheng R., Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. The Journal of Laboratory and Clinical Medicine 2006, 147:126-132.
58. Lin S.M., Du P., Huber W., Kibbe W.A. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Research 2008, 36:e11.
59. Loughland C., Draganic D., McCabe K., Richards J., Nasir A., Allen J., et al. Australian Schizophrenia Research Bank: a database of comprehensive clinical, endophenotypic and genetic data for aetiological studies of schizophrenia. Australian and New Zealand Journal of Psychiatry 2010, 44:1029-1035.
60. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 2009, 24:27-53.
61. Markham J.A., Koenig J.I. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology 2011, 214:89-106.
62. Martins-de-Souza D., Maccarrone G., Wobrock T., Zerr I., Gormanns P., Reckow S., et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. Journal of Psychiatric Research 2010, 44:1176-1189.
63. Maschietto M., Silva A.R., Puga R.D., Lima L., Pereira C.B., Nakano E.Y., et al. Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls. Psychiatry Research 2012, [Epub ahead of print]. 10.1016/j.psychres.2012.04.030.
64. Matigian N., Abrahamsen G., Sutharsan R., Cook A.L., Vitale A.M., Nouwens A., et al. Disease-specific, neurosphere-derived cells as models for brain disorders. Disease Models & Mechanisms 2010, 3:785-798.
65. Maxeiner H.G., Rojewski M.T., Schmitt A., Tumani H., Bechter K., Schmitt M. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain, Behavior, and Immunity 2009, 23:134-142.
66. McGrath J.J., Burne T.H., Feron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophrenia Bulletin 2010, 36:1073-1078.
67. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. Journal of Neuroimmunology 2002, 132:34-40.
68. Meaburn E.L., Fernandes C., Craig I.W., Plomin R., Schalkwyk L.C. Assessing individual differences in genome-wide gene expression in human whole blood: reliability over four hours and stability over 10 months. Twin Research and Human Genetics: The Official Journal of the International Society for Twin Studies 2009, 12:372-380.
69. Meyer U., Feldon J., Schedlowski M., Yee B.K. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain, Behavior, and Immunity 2006, 20:378-388.
70. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics 2011, 132:96-110.
71. Middleton F.A., Pato C.N., Gentile K.L., McGann L., Brown A.M., Trauzzi M., et al. Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2005, 136B:12-25.
72. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 2011, 70:663-671.
73. Mistry M., Gillis J., Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort. Molecular Psychiatry 2012, [Epub ahead of print]. 10.1038/mp.2011.172.
74. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Progress in Neuropsychopharmacology & Biological Psychiatry 2012, 10.1016/j.pnpbp.2011.12.002.
75. Moraleva A.A., Malysheva M.V., Magoulas C., Polzikov M.A., Zatsepina O.V. Early expression of nucleolar SURF-6 protein in mouse spleen lymphocytes activated for proliferation in vitro. Bulletin of Experimental Biology and Medicine 2009, 147:578-582.
76. Muller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Progress in Neuropsychopharmacology & Biological Psychiatry 1998, 22:1-33.
77. Nair P., Melarkode R., Rajkumar D., Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clinical and Experimental Immunology 2010, 162:116-130.
78. Narayan S., Tang B., Head S.R., Gilmartin T.J., Sutcliffe J.G., Dean B., et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Research 2008, 1239:235-248.
79. Nawa H., Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neuroscience Research 2006, 56:2-13.
80. O'Carroll D., Mecklenbrauker I., Das P.P., Santana A., Koenig U., Enright A.J., et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes & Development 2007, 21:1999-2004.
81. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics 2008, 40:1053-1055.
82. Owen D., Andrews M.H., Matthews S.G. Maternal adversity, glucocorticoids and programming of neuroendocrine function and behaviour. Neuroscience and Biobehavioral Reviews 2005, 29:209-226.
83. Ozbey U., Tug E., Namli M. Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2009, 10:461-468.
84. Paul-Samojedny M., Owczarek A., Suchanek R., Kowalczyk M., Fila-Danilow A., Borkowska P., et al. Association study of interferon gamma (IFN-gamma) +874T/A gene polymorphism in patients with paranoid schizophrenia. Journal of Molecular Neuroscience: MN 2011, 43:309-315.
85. Potthoff M.J., Olson E.N. MEF2: a central regulator of diverse developmental programs. Development 2007, 134:4131-4140.
86. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008, 63:801-808.
87. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 2011, 43:969-976.
88. Rodriguez-Garcia M., Oliva H., Climent N., Garcia F., Gatell J.M., Gallart T. Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. Journal of Leukocyte Biology 2007, 82:1143-1146.
89. Rollins B., Martin M.V., Morgan L., Vawter M.P. Analysis of whole genome biomarker expression in blood and brain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2010, 153B:919-936.
90. Saetre P., Emilsson L., Axelsson E., Kreuger J., Lindholm E., Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
91. Sallenave J.M. Antimicrobial activity of antiproteinases. Biochemical Society Transactions 2002, 30:111-115.
92. Santarelli D.M., Beveridge N.J., Tooney P.A., Cairns M.J. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biological Psychiatry 2011, 69:180-187.
93. Schaefer A., Im H.I., Veno M.T., Fowler C.D., Min A., Intrator A., et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. Journal of Experimental Medicine 2010, 207:1843-1851.
94. Schmitt A., Bertsch T., Tost H., Bergmann A., Henning U., Klimke A., et al. Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatric Disease and Treatment 2005, 1:171-177.
95. Schmitt A., Leonardi-Essmann F., Durrenberger P.F., Parlapani E., Schneider-Axmann T., Spanagel R., et al. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2011, 12:201-215.
96. Schwalfenberg G.K. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Molecular Nutrition & Food Research 2011, 55:96-108.
97. Selsted M.E., Ouellette A.J. Mammalian defensins in the antimicrobial immune response. Nature Immunology 2005, 6:551-557.
98. Sequeira P.A., Martin M.V., Vawter M.P. The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiology of Disease 2012, 45:23-36.
99. Shao L., Li T., Mo X., Majdic O., Zhang Y., Seyerl M., et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cellular Immunology 2010, 263:188-195.
100. Shao L., Vawter M.P. Shared gene expression alterations in schizophrenia and bipolar disorder. Biological Psychiatry 2008, 64:89-97.
101. She H., Yang Q., Shepherd K., Smith Y., Miller G., Testa C., et al. Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. The Journal of Clinical Investigation 2011, 121:930-940.
102. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
103. Shi L., Fatemi S.H., Sidwell R.W., Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23:297-302.
104. Singh B., Banerjee S., Bera N.K., Nayak C.R., Chaudhuri T.K. Analysis of the role of human leukocyte antigen class-I genes to understand the etiopathology of schizophrenia. Indian Journal of Psychiatry 2008, 50:166-170.
105. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004, 3. Article3.
106. Soderlund J., Schroder J., Nordin C., Samuelsson M., Walther-Jallow L., Karlsson H., et al. Activation of brain interleukin-1beta in schizophrenia. Molecular Psychiatry 2009, 14:1069-1071.
107. Soehnlein O., Kenne E., Rotzius P., Eriksson E.E., Lindbom L. Neutrophil secretion products regulate anti-bacterial activity in monocytes and macrophages. Clinical and Experimental Immunology 2008, 151:139-145.
108. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
109. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics 2002, 71:337-348.
110. Suarez B.K., Duan J., Sanders A.R., Hinrichs A.L., Jin C.H., Hou C., et al. Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. American Journal of Human Genetics 2006, 78:315-333.
111. Subramaniyam D., Hollander C., Westin U., Erjefalt J., Stevens T., Janciauskiene S. Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis. Respirology 2011, 16:300-307.
112. Sullivan P.F., Fan C., Perou C.M. Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2006, 141B:261-268.
113. Takahashi M., Hayashi H., Watanabe Y., Sawamura K., Fukui N., Watanabe J., et al. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophrenia Research 2010, 119:210-218.
114. Tienari P., Wynne L.C., Laksy K., Moring J., Nieminen P., Sorri A., et al. Genetic boundaries of the schizophrenia spectrum: evidence from the Finnish Adoptive Family Study of Schizophrenia. American Journal of Psychiatry 2003, 160:1587-1594.
115. Tsuang M.T., Nossova N., Yager T., Tsuang M.M., Guo S.C., Shyu K.G., et al. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2005, 133B:1-5.
116. Tynan R.J., Weidenhofer J., Hinwood M., Cairns M.J., Day T.A., Walker F.R. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain, Behavior, and Immunity 2012, 26:469-479.
117. Wager-Smith K., Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?. Neuroscience and Biobehavioral Reviews 2011, 35:742-764.
118. Wang Z.Z., Li G., Chen X.Y., Zhao M., Yuan Y.H., Wang X.L., et al. Chemokine-like factor 1, a novel cytokine, induces nerve cell migration through the non-extracellular Ca2+-dependent tyrosine kinases pathway. Brain Research 2010, 1308:24-34.
119. Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: structure, function and therapeutic potential. Expert Reviews in Molecular Medicine 2008, 10:e17.
120. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. Journal of Psychiatric Research 2005, 39:311-323.